Helix BioPharma Corp.

TSX:HBP.TO

Biotechnology

Healthcare
$0.86 -4.70%

-$0.07 today

Market cap
$65.69M
Beta
-0.29
P/E (TTM)
-32.6
EPS (TTM)
-$0.04
52W Low $0.84High $5.40

Volume 0.00M

Average 0.00M

HBP.TO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Helix BioPharma Corp.TSX: HBP.TO

Gross Profit · Q3 FY2026 · quarter ended Apr 2026

Gross profit remains negative

Q3 FY2026 gross profit was -CA$1K, compared with -CA$3K a year earlier. Trailing-twelve-month gross profit was -CA$5K.

Context

  • Gross profit grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -CA$1K or moves back toward the trailing-twelve-month quarterly average of -CA$1.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
-CA$1K+0.0% QoQ
Last fiscal yearJul 2025
-CA$10K+28.6% YoY
LTMApr 2026
-CA$5K+37.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+66.7%——
1 year+28.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

CAD · from the income statement

Latest · FY2025
(10K) CAD
Year-over-year change
+28.6%

Gross Profit vs competitors

How HBP.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +37.5% is the 2nd highest of 4, against a peer median of +23.4%.
HBP.TO Competitors
Gross Profit for HBP.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$34.41M USD-27.0%-24.8%61.7%
HBP.TOHelix BioPharma Corp.LTM Apr 2026-CA$5K CAD+37.5%——
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026-$5.77K USD———
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026-CA$103.71K CAD+23.4%——
SVA.TOSernova Corp.LTM Apr 2026-CA$256.13K CAD+40.2%——
Peer median (excluding HBP.TO) —+23.4%-24.8%61.7%

Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Revenue00000
Cost of Revenue173K12K13K14K10K
Gross Profit(173K)(12K)(13K)(14K)(10K)
Gross Margin—————
Research & Development5.88M4.54M5.28M6.1M3.58M
Selling, General & Admin3.25M595K299K3.26M1.84M
Operating Expenses9.13M6.04M6.33M9.36M5.42M
Depreciation & Amortization173K12K13K14K10K
EBITDA(9.46M)(6.03M)(6.31M)(9.38M)(5.21M)
EBITDA Margin—————
Operating Income(9.61M)(6.54M)(6.28M)(9.37M)(5.43M)
Operating Margin—————
Interest Income154K47K31K17K
Interest Expense15K18K14K7K10K
Other Income / Expenses(443K)(523K)36K(25K)192K
Income Before Tax(9.57M)(6.56M)(6.29M)(9.4M)(5.23M)
Pre-Tax Margin—————
Income Tax Expense(1.66M)(484K)14K(132K)(28K)
Net Income(7.91M)(6.08M)(6.29M)(9.26M)(5.21M)
Net Margin—————
EPS (Basic)(0.29)(0.20)(0.16)(0.21)(0.09)
EPS (Diluted)(0.29)(0.20)(0.16)(0.21)(0.09)
Weighted Avg Shares27.58M29.9M38.65M44.49M55.74M
Weighted Avg Shares (Diluted)27.58M29.9M38.65M44.49M55.74M

Helix BioPharma Corp.

TSX:HBP.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.